295 related articles for article (PubMed ID: 28803965)
21. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.
Seillier A; Advani T; Cassano T; Hensler JG; Giuffrida A
Int J Neuropsychopharmacol; 2010 Apr; 13(3):373-86. PubMed ID: 19607756
[TBL] [Abstract][Full Text] [Related]
23. The CB1 negative allosteric modulator PSNCBAM-1 reduces ethanol self-administration via a nonspecific hypophagic effect.
Buechler HM; Sumi M; Madhuranthakam IM; Donegan C; DiGiorgio F; Acosta AA; Uribe S; Rahman MA; Sorbello A; Fischer BD; Keck TM
Pharmacol Biochem Behav; 2024 Jul; 240():173776. PubMed ID: 38679080
[TBL] [Abstract][Full Text] [Related]
24. Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.
Feliszek M; Bindila L; Lutz B; Zimmer A; Bilkei-Gorzo A; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):603-12. PubMed ID: 26984820
[TBL] [Abstract][Full Text] [Related]
25. Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity.
Dopart R; Lu D; Lichtman AH; Kendall DA
Drug Metab Rev; 2018 Feb; 50(1):3-13. PubMed ID: 29355030
[TBL] [Abstract][Full Text] [Related]
26. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.
Ignatowska-Jankowska BM; Baillie GL; Kinsey S; Crowe M; Ghosh S; Owens RA; Damaj IM; Poklis J; Wiley JL; Zanda M; Zanato C; Greig IR; Lichtman AH; Ross RA
Neuropsychopharmacology; 2015 Dec; 40(13):2948-59. PubMed ID: 26052038
[TBL] [Abstract][Full Text] [Related]
27. CB
Trexler KR; Eckard ML; Kinsey SG
Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
[TBL] [Abstract][Full Text] [Related]
28. Allosteric modulation of the cannabinoid CB1 receptor.
Price MR; Baillie GL; Thomas A; Stevenson LA; Easson M; Goodwin R; McLean A; McIntosh L; Goodwin G; Walker G; Westwood P; Marrs J; Thomson F; Cowley P; Christopoulos A; Pertwee RG; Ross RA
Mol Pharmacol; 2005 Nov; 68(5):1484-95. PubMed ID: 16113085
[TBL] [Abstract][Full Text] [Related]
29. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.
Savinainen JR; Saario SM; Niemi R; Järvinen T; Laitinen JT
Br J Pharmacol; 2003 Dec; 140(8):1451-9. PubMed ID: 14623770
[TBL] [Abstract][Full Text] [Related]
30. Effects of Delta9-tetrahydrocannabivarin on [35S]GTPgammaS binding in mouse brain cerebellum and piriform cortex membranes.
Dennis I; Whalley BJ; Stephens GJ
Br J Pharmacol; 2008 Jul; 154(6):1349-58. PubMed ID: 18493244
[TBL] [Abstract][Full Text] [Related]
31. The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.
Erdozain AM; Diez-Alarcia R; Meana JJ; Callado LF
Biochem Pharmacol; 2012 Jan; 83(2):260-8. PubMed ID: 22093909
[TBL] [Abstract][Full Text] [Related]
32. Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.
Walentiny DM; Vann RE; Warner JA; King LS; Seltzman HH; Navarro HA; Twine CE; Thomas BF; Gilliam AF; Gilmour BP; Carroll FI; Wiley JL
Psychopharmacology (Berl); 2010 Jun; 210(2):275-84. PubMed ID: 20354680
[TBL] [Abstract][Full Text] [Related]
33. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors.
Tham M; Yilmaz O; Alaverdashvili M; Kelly MEM; Denovan-Wright EM; Laprairie RB
Br J Pharmacol; 2019 May; 176(10):1455-1469. PubMed ID: 29981240
[TBL] [Abstract][Full Text] [Related]
34. In vivo evaluation of the CB
Mustafa M; Donvito G; Moncayo L; Swafford A; Poklis J; Grauer R; Olszewska T; Ignatowska-Jankowska B; Kendall DA; Lu D; Lichtman AH
Pharmacol Biochem Behav; 2020 Mar; 190():172840. PubMed ID: 31899221
[TBL] [Abstract][Full Text] [Related]
35. Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.
Ahn KH; Mahmoud MM; Kendall DA
J Biol Chem; 2012 Apr; 287(15):12070-82. PubMed ID: 22343625
[TBL] [Abstract][Full Text] [Related]
36. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
[TBL] [Abstract][Full Text] [Related]
37. The membrane proximal region of the cannabinoid receptor CB1 N-terminus can allosterically modulate ligand affinity.
Fay JF; Farrens DL
Biochemistry; 2013 Nov; 52(46):8286-94. PubMed ID: 24206272
[TBL] [Abstract][Full Text] [Related]
38. The future of type 1 cannabinoid receptor allosteric ligands.
Alaverdashvili M; Laprairie RB
Drug Metab Rev; 2018 Feb; 50(1):14-25. PubMed ID: 29355038
[TBL] [Abstract][Full Text] [Related]
39. Sex, species and age: Effects of rodent demographics on the pharmacology of ∆
Wiley JL; Barrus DG; Farquhar CE; Lefever TW; Gamage TF
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 106():110064. PubMed ID: 32810571
[TBL] [Abstract][Full Text] [Related]
40. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
